Last reviewed · How we verify
navicixizumab monotherapy
At a glance
| Generic name | navicixizumab monotherapy |
|---|---|
| Sponsor | OncXerna Theraputics, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors (PHASE2)
- A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- navicixizumab monotherapy CI brief — competitive landscape report
- navicixizumab monotherapy updates RSS · CI watch RSS
- OncXerna Theraputics, Inc. portfolio CI